Literature DB >> 21347644

Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review.

Yoshiyuki Kurata1, Kingo Fujimura2, Masataka Kuwana3, Yoshiaki Tomiyama4, Mitsuru Murata5.   

Abstract

The epidemiology of primary immune thrombocytopenia (ITP) is not well-characterized in the general population. Most published studies, which have included relatively small numbers of ITP patients, have been conducted in England or Scandinavian countries. No epidemiologic data from Asian countries have been published. This study describes the epidemiology of ITP in a Japanese population. We analyzed the database registry of the Ministry of Health, Labour, and Welfare of Japan, and extracted newly diagnosed acute and chronic ITP patients with a platelet count of <100 × 10(9)/L. From 2004 to 2007, 7,774 cases of ITP were reported, giving an overall incidence of 2.16/100,000/year. The incidence differed greatly between males and females, being 1.72 and 2.58, respectively. The median age of the total affected population was 56 years old. In male patients, there was a striking preponderance of boys below 4 years and a very high peak among those aged 75-89 years. In female patients, the number of ITP patients appeared to show a trimodal distribution by age, with the first peak representing patients below 4 years, the second peak those aged 20-34 years, and the third peak those aged 50-89 years. In conclusion, the incidence of ITP in Japan is not markedly different from that of European countries studied to date. This population-based study reveals that, contrary to previously published studies, the maximum age-specific incidence is in the eighth decade.

Entities:  

Mesh:

Year:  2011        PMID: 21347644     DOI: 10.1007/s12185-011-0791-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

1.  Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.

Authors:  Robert McMillan; Lei Wang; Aaron Tomer; Janet Nichol; Jeanne Pistillo
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

Review 2.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

3.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

4.  Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines.

Authors:  P H Bolton-Maggs; I Moon
Journal:  Lancet       Date:  1997-08-30       Impact factor: 79.321

5.  The incidence of idiopathic thrombocytopenic purpura in adults increases with age.

Authors:  H Frederiksen; K Schmidt
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

6.  Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease.

Authors:  Bernward Zeller; Jukka Rajantie; Iris Hedlund-Treutiger; Ulf Tedgård; Finn Wesenberg; Olafur G Jonsson; Jan Inge Henter
Journal:  Acta Paediatr       Date:  2005-02       Impact factor: 2.299

7.  Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration.

Authors:  B Zeller; J Helgestad; M Hellebostad; S Kolmannskog; T Nystad; K Stensvold; F Wesenberg
Journal:  Pediatr Hematol Oncol       Date:  2000 Oct-Nov       Impact factor: 1.969

Review 8.  The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports.

Authors:  Deirdra R Terrell; Laura A Beebe; Sara K Vesely; Barbara R Neas; Jodi B Segal; James N George
Journal:  Am J Hematol       Date:  2010-03       Impact factor: 10.047

9.  [Epidemiological aspects of idiopathic thrombocytopenic purpura in Kochi Prefecture].

Authors:  Isao Takahashi; Seiichi Yorimitsu
Journal:  Rinsho Ketsueki       Date:  2004-05

10.  Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database.

Authors:  W Marieke Schoonen; Gena Kucera; Jenna Coalson; Lin Li; Mark Rutstein; Fionna Mowat; Jon Fryzek; James A Kaye
Journal:  Br J Haematol       Date:  2009-02-24       Impact factor: 6.998

View more
  23 in total

1.  Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan.

Authors:  Takaaki Hato; Naoki Shimada; Yoshiyuki Kurata; Masataka Kuwana; Kingo Fujimura; Hirokazu Kashiwagi; Toshiro Takafuta; Mitsuru Murata; Yoshiaki Tomiyama
Journal:  Blood Adv       Date:  2020-04-28

2.  Ischemic stroke in pediatric moyamoya disease associated with immune thrombocytopenia--a case report.

Authors:  Tomohide Hayashi; Naoki Akioka; Daina Kashiwazaki; Naoya Kuwayama; Satoshi Kuroda
Journal:  Childs Nerv Syst       Date:  2015-02-08       Impact factor: 1.475

3.  An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).

Authors:  Yukari Shirasugi; Kiyoshi Ando; Koji Miyazaki; Yoshiaki Tomiyama; Koji Iwato; Shinichiro Okamoto; Mineo Kurokawa; Keita Kirito; Satoshi Hashino; Haruhiko Ninomiya; Shinichiro Mori; Yuji Yonemura; Kensuke Usuki; Helen Wei; Richard Lizambri
Journal:  Int J Hematol       Date:  2012-04-25       Impact factor: 2.490

4.  Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.

Authors:  Yoshitaka Miyakawa; Shinya Katsutani; Takahiro Yano; Shosaku Nomura; Kaichi Nishiwaki; Yoshiaki Tomiyama; Masaaki Higashihara; Yukari Shirasugi; Masakatsu Nishikawa; Katsutoshi Ozaki; Takayuki Abe; Kayoko Kikuchi; Yuzuru Kanakura; Kingo Fujimura; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2015-12       Impact factor: 2.490

5.  Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.

Authors:  Yukari Shirasugi; Kiyoshi Ando; Koji Miyazaki; Yoshiaki Tomiyama; Shinichiro Okamoto; Mineo Kurokawa; Keita Kirito; Yuji Yonemura; Shinichiro Mori; Kensuke Usuki; Koji Iwato; Satoshi Hashino; Helen Wei; Richard Lizambri
Journal:  Int J Hematol       Date:  2011-06-25       Impact factor: 2.490

6.  Chronic adult primary immune thrombocytopenia (ITP) in the Asia-Pacific region.

Authors:  Lee Lai Heng; Priscilla Caguioa; Ng Soo Chin; Tzeon-Jye Chiou; Jong Wook Lee; Yoshitaka Miyakawa; Karmel L Tambunan; Beng H Chong
Journal:  Int J Hematol       Date:  2011-07-16       Impact factor: 2.490

7.  Seasonal Association of Immune Thrombocytopenia in Adults.

Authors:  Anıl Tombak; Burcu Boztepe; Naci Tiftik; Melda Cömert; Ozan Salim; Kaniye Aydın; Emel Gürkan; Orhan Kemal Yücel; Güray Saydam; Mehmet Ali Sungur
Journal:  Balkan Med J       Date:  2015-10-01       Impact factor: 2.021

Review 8.  Pathophysiology and management of primary immune thrombocytopenia.

Authors:  Hirokazu Kashiwagi; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2013-05-24       Impact factor: 2.490

9.  Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database.

Authors:  Keiko Ogawa; Yoshihiro Kozuka; Hitomi Uno; Kosuke Utsumi; Osamu Noyori; Rumiko Hosoki
Journal:  Clin Drug Investig       Date:  2021-06-10       Impact factor: 2.859

10.  Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.

Authors:  Shinya Katsutani; Yoshiaki Tomiyama; Akiro Kimura; Yoshitaka Miyakawa; Shinichiro Okamoto; Yasushi Okoshi; Haruhiko Ninomiya; Hiroshi Kosugi; Kazuyoshi Ishii; Yasuo Ikeda; Toshihiro Hattori; Koichi Katsura; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2013-07-30       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.